Across TCGA pan-cancer cohorts, PRSS57 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated PRSS57 data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PRSS57 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PRSS57 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

PDAC and LSCC are the cancer types where PRSS57 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.497	1.000	<.001	36	view →
LSCC	DFS	Tertile	III,IV	0.958	0.540	.022	3	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: PRSS57 tumor-vs-normal RNA expression · all PRSS57 data types